NCT06458075
Intervention to Improve Communication and Medication Adherence in Lupus
Recruiting · Not Applicable · Duke University · registry updated 2026-08-17
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the following: 1. clinicians will be provided with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill date, engage and formulate solutions to adherence barriers, and collaboratively overcome adherence barriers. 2. use of a reliable and valid patient-reported measure of the extent of and reasons for nonadherence that helps patients identify and communicate their adherence barriers with clinicians proactively, efficiently, and comprehensively.
Inclusion
- Adult rheumatology attendings, advanced practice providers, and fellows at the two academic institutions
- Clinicians who have ambulatory rheumatology care at least ½ day per week
Exclusion
- Clinicians at Duke University who were involved in the investigators' pilot work
- Clinicians with an anticipated departure from the institution in the 12 months following enrollment
- Patient Inclusion Criteria:
- years or older
- English-speaking, able to provide consent
- Diagnosed with SLE and receiving care with enrolled clinicians